Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)
Completed
This pilot study is proposed to determine the acceptability, feasibility and potential efficacy of ketamine, a medication that modulates glutamate in the brain, as a rapid treatment for obsessive-compulsive disorder (OCD) symptoms in adolescents and young adults with OCD. This study will recruit 6 youth (ages 14-22) who are diagnosed with clinically significant OCD and have failed at least one adequate trial of a Serotonin Reuptake Inhibitor (SRI) medication and a course of Cognitive-Behavioral... Read More
Gender:
ALL
Ages:
Between 14 years and 22 years
Trial Updated:
08/14/2020
Locations: New York State Psychiatric Institute/Columbia University, New York, New York
Conditions: Obsessive-Compulsive Disorder
A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)
Completed
This is a multi-site, double-blind, placebo-controlled study of the acute efficacy of brexpiprazole or placebo in combination with intranasal ketamine added to ongoing, stable, and adequate antidepressant therapy (ADT) in the treatment of adults with Major Depressive Disorder with Treatment Resistant Depression.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/16/2020
Locations: Montefiore Medical Center, Bronx, New York +1 locations
Conditions: Depression
Ketamine and Nitroprusside for Depression
Completed
The purpose of this study is to test the effects of the medication ketamine and the medication called nitroprusside in patients with major depression. Ketamine has both good and bad effects. Some studies have shown that ketamine improves depression. However, studies have also shown that it causes strange and sometimes unpleasant sensations referred to "psychotic" or "dissociative" symptoms. An example of a psychotic symptom would be hearing or seeing something that in reality is not there. The s... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
07/01/2020
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Depression
Ketamine in the Treatment of Suicidal Depression
Completed
This study is designed to compare the effectiveness of two medications, Ketamine and Midazolam, for rapidly relieving suicidal thoughts in people suffering from depression. The first drug, Ketamine, is an experimental antidepressant that early studies have shown may quickly reduce suicidal thoughts, but we are not sure how well it may work. Midazolam, the comparison drug, is not thought to reduce depression or suicidal thoughts.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/10/2020
Locations: Columbia University/New York State Psychiatric Institute, New York, New York
Conditions: Major Depressive Disorder, Suicidal Ideation
Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy
Completed
This is a randomized, double-blind, placebo-controlled, two-arm parallel, single-center study. One hundred subjects (50 in each arm) will be enrolled. Subjects, between the ages 18 and 65, undergoing laparoscopic gastric bypass or sleeve gastrectomy will be recruited and consented during the preadmission visit prior to surgery.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/02/2020
Locations: NYU Langone Medical Center, New York, New York
Conditions: Pain, Postoperative Depression
Ketamine for Suicidality in Bipolar Depression
Completed
This study is designed to compare the effectiveness of two medications, Ketamine and Midazolam, for rapidly relieving suicidal thoughts in people suffering from bipolar depression. The first drug, ketamine, is an experimental antidepressant that early studies have shown may quickly reduce suicidal thoughts, but we are not sure how well it may work. Midazolam, the comparison drug, is not thought to reduce depression or suicidal thoughts.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/27/2020
Locations: Columbia University/New York State Psychiatric Institute, New York, New York
Conditions: Bipolar Disorder, Major Depressive Episode, Suicidal Ideation
Facilitating the Behavioral Treatment of Cannabis Use Disorder
Completed
Cannabis use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered cannabis use. Cannabis use disorders are recognized to be associated with various vulnerabilities that complicate the course of treatment and that may be amenable to glutamate modulators. The purpose of this single blind open-label trial is to test the feasibility of administering glutamate modulators in conjunction... Read More
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
01/31/2020
Locations: NYSPI, New York, New York
Conditions: Cannabis Dependence
Glutamatergic Modulation of Disordered Alcohol Use
Completed
Alcohol use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered drinking. Alcohol use disorders are recognized to be associated with various vulnerabilities that complicate the course of treatment and that may be amenable to glutamate modulators. The purpose of this randomized, double-blind, controlled trial is to test various glutamate modulators in conjunction with motivational... Read More
Gender:
ALL
Ages:
Between 21 years and 69 years
Trial Updated:
01/31/2020
Locations: NYSPI, New York, New York
Conditions: Alcohol Dependence
Ketamine and Propofol Combination Versus Propofol for Upper Gastrointestinal Endoscopy
Terminated
Propofol is one of the most popular anesthetic drugs used for sedation during upper gastrointestinal endoscopies due to its quick onset and quick resolution of symptoms allowing patients to leave the hospital sooner. However, when administered it can also slow the breathing of patients and cause others to have upper airway obstruction (such as snoring) which can impede proper spontaneous breathing. Ketamine is an agent that is capable of providing both pain control and sedation while having eith... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2020
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Obesity, Bariatrics, Sleep Apnea Syndromes, Gastric Bypass, Endoscopy
Ketamine in the Treatment of Depression
Completed
Depressed patients will be offered experimental treatment with a new, potentially fast-acting antidepressant called ketamine while being scanned by magnetic resonance imaging (MRI) to measure the chemical effect of the drug. Ketamine will be given in a dose of 0.0 (placebo), 0.1, 0.2, 0.3, 0.4, or 0.5 mg/kg. If a patient does not respond to ketamine after the first infusion, it may be because s/he received ketamine placebo or the dose of ketamine was too low. In that case, an optional second sca... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/03/2019
Locations: New York State Psychiatric Institute, New York, New York
Conditions: Major Depressive Disorder
Spinal Versus General Anesthesia With Popliteal and Adductor Canal Blocks for Ambulatory Foot and Ankle Surgery.
Completed
The purpose of this study is to determine if there is a difference in patient outcomes with general anesthesia versus spinal anesthesia when given in addition to popliteal and adductor canal nerve blocks for foot and ankle surgery. Popliteal and adductor canal nerve blocks are injections of local anesthetic agents near nerves in the back and front of the knee going to the foot and ankle that provide numbness during and after surgery. These peripheral nerve blocks offer good pain control and redu... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/07/2019
Locations: Hospital for Special Surgery, New York, New York, New York
Conditions: Nerve Block, General Anesthesia, Spinal Anesthesia, Pain, Postoperative Nausea and Vomiting
Research Study for Major Depressive Disorder: Investigation of Glutamate Medications
Completed
This study is examining the safety and effectiveness of two medications, ketamine and riluzole, in treating patients with treatment resistant major depressive disorder. This study will also examine the effectiveness of an FDA approved drug called lamotrigine in decreasing the potential side effects associated with ketamine.
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
07/16/2019
Locations: Mount Sinai School of Medicine, New York, New York
Conditions: Major Depression